EGFR and non-small cell lung carcinoma: A phase III study, AURA3, showed that for patients with EGFR T790M advanced NSCLC previously treated with EGFR-TKI, the progression-free survival (PFS) of osimertinib arm was 10.1 months, significantly higher than that of the platinum-pemetrexed arm (4.4 months) (10).